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Abstract
Purpose: Dosimetric evaluations of single and multiple liver tumours performed using intensity-modulated helical 
tomotherapy (HT) were quantitatively investigated. Step-and-shoot intensity-modulated radiotherapy (SaS-IMRT) was 
used as a benchmark.
Methods: Sixteen patients separated into two groups with primary hepatocellular carcinomas or metastatic liver 
tumours previously treated using SaS-IMRT were examined and re-planned by HT. The dosimetric indices used 
included the conformity index (CI) and homogeneity index (HI) for the planned target volume (PTV), max/mean dose, 
quality index (QI), normal tissue complication probability (NTCP), V30 Gy, and V50% for the specified organs at risk (OARs). 
The monitor units per fraction (MU/fr) and delivery time were also analysed.
Results: For the single tumour group, both planning systems satisfied the required PTV prescription, but no statistical 
significance was shown by the indexes checking. A shorter delivery time and lower MU/fr value were achieved by the 
SaS-IMRT. For the group of multiple tumours, the average improvement in CI and HI was 14% and 4% for HT versus SaS-
IMRT, respectively. Lower V50%, V30 Gy and QI values were found, indicating a significant dosimetric gain in HT. The NTCP 
value of the normal liver was 20.27 ± 13.29% for SaS-IMRT and 2.38 ± 2.25% for HT, indicating fewer tissue 
complications following HT. The latter also required a shorter delivery time.
Conclusions: Our study suggests dosimetric benefits of HT over SaS-IMRT plans in the case of multiple liver tumours, 
especially with regards sparing of OARs. No significant dosimetric difference was revealed in the case of single liver 
tumour, but SaS-IMRT showed better efficiency in terms of MU/fr and delivery time.
Background
During the past 20 years, primary liver cancer has ranked
the fifth most common malignancy worldwide, the third
leading cause of death from malignant neoplasm in Japan
in men and the fifth in women [1,2], and the second lead-
ing cause of cancer death in Taiwan with a mortality of
more than 7,000 cases each year [3]. Several modalities
have been used for the treatment of hepatocellular carci-
nomas (HCC) and metastatic liver tumours [4-10] includ-
ing surgery, transcatheter arterial chemoembolization
(TACE), percutaneous ethanol injection therapy, micro-
wave coagulation therapy, radiotherapy and liver trans-
plantation. The role of radiotherapy has been limited
because of the poor tolerance of the whole liver to radia-
tion [11,12]. With advances in intensity-modulated radia-
tion therapy (IMRT), several reports have indicated
increased safety and more promising results in patients
with unresectable intrahepatic malignancies treated with
radiotherapy to a portion of the liver [6,13-18]. IMRT
constitutes an advanced form of the conformal technique
and uses inverse planning algorithms and iterative com-
puter-driven optimization to generate treatment fields
with varying beam intensity. It has the ability to produce
custom-tailored conformal dose distributions around the
tumour, although most studies have examined large
tumours [19]. IMRT can also be delivered using linac or
Hi-Art Helical Tomotherapy (HT) (TomoTherapy, Madi-
son, WI, USA), which creates a more uniform target dose
and improves critical organ sparing [16,20-23] with a
greater number of degrees of freedom.
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Compared with conventional and other IMRT tech-
niques, HT can potentially produce superior dose distri-
butions (i.e., more uniform dose to the target and lower
doses to normal tissues) and is thus being reconsidered
for promotion [21,22,24]. In this study, we investigated
the potential improvement of HT over step-and-shoot
(SaS)-IMRT for the treatment of single or multiple liver
tumours. HT plans were compared with IMRT plans for
sixteen patients previously treated using SaS-IMRT deliv-
ery. The HT plans were designed to emulate as closely as
possible the goals and constraints used for SaS-IMRT
plans. Dose distributions in the planned target volume
(PTV) and organs at risk (OARs) were compared accord-
ing to the isodose distribution and dose-volume histo-
gram (DVH)-based method using several dosimetric
parameters including the conformity index (CI) and
homogeneity index (HI) for the PTV, max/mean dose,
quality index (QI) for the organs at risk (OARs) [25-29],
V30 Gy, V50%, EUD (equivalent uniform dose), and NTCP
(normal tissue complication probabilities) for the normal
and whole liver. The delivery time and monitor units per
fraction (MU/fr) of the two techniques were also com-
pared. SaS-IMRT was used as a benchmark.
Methods
Study population
Sixteen consecutive patients (six females, ten males) with
primary hepatocellular carcinomas (HCC) or metastatic
liver tumours previously treated using SaS-IMRT
between March 2006 and March 2008 were examined.
The patient characteristics and tumour descriptions are
presented in Table 1. The median age was 68 years (range
50-85). Patients were retrospectively grouped to evaluate
the influence of the treatment plans. Two groups were
formed according to whether they had single (group 1) or
multiple (group 2) tumour sites, and interestingly, there
were eight in each group. The distributions of clinical
stages according to the American Joint Committee on
Cancer (AJCC 6th edition) staging system was as follows;
I: 1 (6.25%), II: 3 (18.75%), III: 5 (31.25%) and metastasis
liver tumour: 7 (43.75%). Six (37.5%) were treated with a
combination of chemotherapy.
All patients were immobilized using a tailor-made vac-
uum lock in the supine position with their arms placed on
their forehead. The patients were scanned using a CT
(Siemens Biograph LSO PET/CT, PA, USA) with a 3-mm
slice thickness, containing 512 × 512 pixels in each slice.
The field of view had a mean dimension of 48 cm.
Treatment plans were originally calculated with the
ADAC Pinnacle3, version 7.4 (ADAC Inc, CA, USA)
treatment-planning system (TPS) on a dose grid of 0.4 ×
0.4 × 0.3 cm3 without DMPO (direct machine parameter
optimization). The 5-field and range 4 × 6 SaS-IMRT
technique was used with the dose goal for PTV coverage;
initial gantry angles of 20°, 310°, 270°, 220° and 180° were
set. The plan was delivered on an Elekta Precise™ Linac
equipped with an 80-leaf 1-cm MLC in SaS-IMRT mode.
Basically, the IMRT planning system tried to achieve the
dose goal target coverage while keeping within the dose
constraints of OARs by sequential iteration.
PTV and normal organ contouring
The planned target volume (PTV) structures were cre-
ated from the gross tumour volume (GTV) structures.
Respiratory motion is the main determinant of PTV
expansion. PTVs were based on a 5 mm radial expansion
and a 10 mm craniocaudal expansion. Because respira-
tory motion has been shown to be greater in the cranio-
caudal dimension than in the anteroposterior and
mediolateral dimensions, an asymmetric expansion was
used for the PTV [30-33]. The PTV ranged from 57.75 to
726.32 cc (222.77 ± 170.35). For dosimetric analysis, the
normal liver volume did not include the PTV. The OARs
used in this study were as follows: 1) spinal cord-maxi-
mum dose ≤ 45 Gy; 2) kidneys (L & R)-mean dose to
bilateral kidneys must be < 16 Gy. If only one kidney is
present, not more than 15% of the volume of that kidney
can receive ≥ 18 Gy and no more than 30% can receive ≥
14 Gy; 3) liver-mean liver dose must be ≤ 25 Gy; 4) gas-
Table 1: Patient characteristics (n = 16)
Characteristics No. of patients
Age, median years (range) 68 (50-85)
Gender
Male 10 (62.5%)
Female 6 (37.5%)
Primary HCC (AJCC, 6th edition)
I1  ( 6 . 2 5 % )
II 3 (18.75%)
III 5 (31.25%)
Metastasis liver tumour 
Structures (cm3) Mean ± SD 
(range)
7 (43.75%)
PTV 222.77 ± 170.35 (57.75-726.32)
Normal liver 1299.88 ± 279.03 (751.03-1776.16)
Rt kidney 132.7 ± 50.19 (35.39-238.91)
Lt kidney 147.62 ± 42.82 (78.54-233.17)
Spinal cord 14.10 ± 5.52 (4.93-26.44)
Patient's tumour number
Single (group 1) 8(50%)
Multiple (group 2) 8(50%)
Abbreviation: HCC: Hepatocellular Carcinoma; AJCC = American Joint 
Committee on Cancer; PTV: Planned target volume; Rt: Right side; Lt: 
Left side;Lee et al. Radiation Oncology 2010, 5:58
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trointestinal system (GIS) (including stomach and small
bowels)-maximum dose ≤ 54 Gy; < 10% of each organ
volume can receive between 50 and 53.99 Gy, < 15% of
the volume of each organ can receive between 45 and
49.99 Gy.
Treatment plans
In the re-planned HT, three main parameters were
selected: the field width (1, 2.5 or 5 cm), pitch (range
0.01-20), and modulation factor (range 1-10). A 2.5-cm
field width, a pitch of 0.287 (0.86/3) and a modulation
factor of 2 were used in all of the HT plans in this study
[34,35]. The software version used for this re-planning
study was Hi-Art TomoPlan 2.1 (Tomotherapy Inc., Wis-
consin, USA). The selection of these three parameter val-
ues was based on preliminary planning exercises that
showed them to provide a good balance between ability at
dose sculpting and treatment efficiency, in terms of treat-
ment duration and feasibility for routine use. In general,
small field dimensions, small pitch and large modulation
factors mean longer irradiation times and a better ability
for the delivery system to sculpt complex dose distribu-
tions with steeper dose gradients [16,21,23,24,36]. For all
patients, dose calculation was done on the fine grid,
which has a resolution of 1.875 × 1.875 mm2 by the slice
thickness of 3 mm for the dose calculation window of 48
× 48 cm2 (256 × 256 pixels). Both planning systems per-
form iterations during the optimization process. The 0.1
Gy dose bin-size of the dose-volume histograms (DVHs)
used in both systems was the same for the subsequent
computation of various indices. Plans were run with the
goal of delivering the prescribed doses of 60 Gy/30 frac-
tions while meeting the normal tissue constraints for
conventional treatment. The PTV doses were prescribed
to cover over 95% of the PTV with no greater than a 107%
maximum point dose. Having achieved these objectives,
the dose plans were made by the same physicist and
approved by the same oncologist, who was specialized in
liver tumours. The monitor units per fraction (MU/fr),
segments and delivery time taken by the two plans were
compared. The patient set-up time was not included.
Plan evaluation
The HT plans were compared with the SaS-IMRT plans
using the following dosimetric parameters:
1. CI: a ratio used to evaluate the goodness of fit of the
PTV to the prescription isodose volume in the treat-
ment plans: where VTV is the treat-
ment volume of the prescribed isodose lines; VPTV is
the volume of the PTV; and TVPV is the volume of
VPTV within the VTV. The smaller and closer the value
of CI is to 1, the better the dose conformity [26,37].
2. HI: a ratio used to evaluate the homogeneity of the
PTV. where  D5% and  D95 are the mini-
mum doses delivered to 5% and 95% of the PTV. A
larger HI indicates poorer homogeneity [38,39].
3. QI: an index used to evaluate the difference in the
maximum or mean absorbed dose at serial or parallel
OARs, respectively, between HT and SaS-IMRT plans
[22,40].
4.  V50%: the percentage volume receiving a dose
greater than or equal to 50% of the prescribed dose
for a normal liver.
5.  V30 Gy: the percentage volume receiving a dose
greater than or equal to 30 Gy for the whole liver.
6. EUD: equivalent uniform dose, the original defini-
tion of the EUD was derived on the basis of a mecha-
nistic formulation using a linear-quadratic cell
survival model [41]. Subsequently, Niemierko and
Emami suggested a phenomenological model of the
form [42]:
where α is a unitless model parameter that is specific to
the normal structure or tumour of interest, and νi is unit-
less and represents the ith partial volume receiving dose
Di in Gy. Since the relative volume of the whole structure
of interest corresponds to 1, the sum of all partial vol-
umes vi will equal 1. For normal tissues, the EUD repre-
sents the uniform dose that leads to the same probability
of injury as the examined inhomogeneous dose distribu-
tion.
7. NTCP: an EUD-based normal tissue complication
probability (NTCP) was used. Niemierko proposed
parameterization of the dose-response characteristics
using the logistic function [42,43]:
where TD50 is the tolerance dose for a 50% complication
rate at a specific time interval (e.g., 5 years in the Emami
et al. normal tissue tolerance data [44]) when the whole
organ of interest is homogeneously irradiated, and γ50 is a
unitless model parameter that is specific to the normal
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structure and describes the slope of the dose-response
curve. Niemierko and Emami suggested that the parame-
ters of α and γ50 should be used in the EUD-based NTCP
model. The values of α, γ50, and TD50 used in this study
were 3, 3, and 40 Gy respectively, and were based on the
Emami data, calculating the BED as 2 Gy/fraction with an
α/β ratio of 2 [42,44]. The Matlab-2009a software (Math-
Works, Inc., Natick, Massachusetts) was used for EUD-
based NTCP and CERR (computational environment for
radiotherapy research) calculations [45].
Statistical analyses
The mean values (standard deviation) of the dosimetric
data for the sixteen patients were analysed using the
paired Wilcoxon signed-rank test to compare the differ-
ence between HT and SaS-IMRT. A two-tailed value of p
< 0.05 was deemed to indicate statistical significance. The
SPSS-15.0 software was used for data processing (SPSS,
Inc., Chicago, IL).
Results
PTV analysis
The isodose distributions in the axial plane and the DVHs
of the PTV and OARs for one typical case in each group
plan using both systems are shown in Figs. 1 and 2.
Table 2 gives the dose statistics for the PTV for each
group with HT and SaS-IMRT.
For group 1, the mean V95% and V100% for the desired
PTV coverage was 99.44 ± 0.72 and 97.26 ± 1.13 in the
HT plans, and 99.63 ± 0.51 and 97.84 ± 0.99 in the SaS-
IMRT plans, respectively, with no significant differences
between plans. For the hot spot checking, the mean V107%
for the desired PTV was 0.00 ± 0.00 with HT and 8.75 ±
4.94 with SaS-IMRT respectively, indicating significantly
better homogeneity of the PTV with HT (p < 0.05). (Vx%:
volume receiving ≥x% of the prescribed dose).
The mean CI for group 1 was 1.21 ± 0.07 with HT and
1.30 ± 0.05 with SaS-IMRT, indicating a significantly bet-
ter conformity of the PTV with HT (p < 0.05) The average
improvement in CI was 7% for HT. The mean HI was 1.04
± 0.01 for HT and 1.06 ± 0.01 for SaS-IMRT; this differ-
ence was statistically significant (p  < 0.05) with a 2%
improvement in HT.
For group 2, the mean V95% and V100% for the desired
PTV coverage was 99.09 ± 0.45 and 96.20 ± 0.70 in the
HT plans, and 98.47 ± 0.69 and 96.13 ± 1.10 in the SaS-
IMRT plans, respectively, with no significant difference
between plans. For the hot spot checking, the mean V107%
for the desired PTV was 0.30 ± 0.58 with HT and 16.62 ±
2.38 with SaS-IMRT respectively, indicating significantly
better homogeneity of the PTV with HT (p < 0.05).
The mean CI was 1.25 ± 0.11 with HT and 1.43 ± 0.07
with SaS-IMRT, indicating significantly better conformity
of the PTV with HT (p < 0.05). The average improvement
in CI was 14% for HT versus SaS-IMRT. The mean HI for
group 2 was 1.06 ± 0.01 for HT and 1.10 ± 0.02 for SaS-
IMRT; this difference was statistically significant (p  <
0.05) with a 4% improvement in HT.
Dosimetry of OARs
The dose statistics of the specified OARs are summarized
in Table 3. For group 1, the mean dose, V50% and NTCP
value of the normal liver did not differ significantly
between the HT and SaS-IMRT plans (p > 0.05). Similarly
there was no significant difference between plans in the
V30 Gy value of the whole liver (p > 0.05) or the max/mean
dose of the other four OARs (R/Lt kidneys, GIS, and spi-
nal cord) (p > 0.05).
For group 2, the mean dose, V50% and NTCP value of
the normal liver were significantly lower in the HT plans
versus the SaS-IMRT plans (p < 0.05). The V50% value of
the normal liver was 36.46 ± 4.92% for HT and 51.74 ±
11.46% for SaS-IMRT, indicating an approximate reduc-
tion of 15% in HT. With regards tissue complications the
NTCP value of the normal liver was 2.38 ± 2.25% for HT
and 20.27 ± 13.29% for SaS-IMRT, indicating an approxi-
mate reduction of 18% in HT (NTCP for liver failure).
The V30 Gy value of the whole liver differed significantly
between plans (p < 0.05). The mean value of V30 Gy for the
whole liver was 43.91 ± 10.43% for HT and 55.00 ±
14.28% for SaS-IMRT, indicating an approximate 11%
reduction in HT. The max/mean dose of the following
three OARs (R/Lt kidneys and GIS) did not differ signifi-
cantly. The maximum dose of the spinal cord was 18.08 ±
5.38 for HT and 23.55 ± 8.65 Gy for SaS-IMRT. These
results indicate a significant dosimetric gain in HT and a
reduced dose to sensitive structures.
QI analysis for the OARs
The QI values of the OARs for group 1 and group 2 are
listed in Table 4; the kidneys were excluded in the QI cal-
culation as the test results did not differ significantly.
For group 1, of the two serial OARs, the spinal cord
showed the most notable improvement [QI = 0.86 ± 0.47]
followed by GIS [QI = 0.91 ± 0.23], indicating an approxi-
mate 14% reduction in maximal dose in the spinal cord
and a 9% reduction in the GIS in the HT versus SaS-
IMRT plans, respectively (p > 0.05). Of the only parallel
organ (normal liver) calculated, the QIParellel was 0.95 ±
0.20, indicating an approximate mean dose reduction of
5% in the normal liver in the HT versus SaS-IMRT plans.
For group 2, of the two serial OARs, the spinal cord
showed the most notable improvement [QI = 0.83 ± 0.30]
followed by the GIS [QI  = 0.95 ± 0.12], indicating an
approximate 17% reduction in maximal dose in the spinal
cord and a 5% reduction in the GIS in the HT versus SaS-Lee et al. Radiation Oncology 2010, 5:58
http://www.ro-journal.com/content/5/1/58
Page 5 of 10
IMRT plans, respectively. Of the only parallel organ (nor-
mal liver) calculated, the QIParellel was 0.93 ± 0.17, indicat-
ing an approximate mean dose reduction of 7% in the
normal liver by HT.
For the whole study cohort, of the two serial OARs, the
spinal cord showed the most notable improvement [QI =
0.85 ± 0.38] followed by the GIS [QI = 0.93 ± 0.18], indi-
cating an approximate 15% reduction in maximal dose in
the spinal cord and a 7% reduction in the GIS by HT. Of
the only parallel (normal liver) organ calculated, the QI
was 0.93 ± 0.17, indicating an approximate mean dose
reduction of 7% in the normal liver by HT.
MU/fr and delivery time
The MU/fr and delivery time of the sixteen patients with
HT versus SaS-IMRT are compared in Table 5. For group
1, the mean delivery time was 4.4 ± 1.4 min (range 2.9-
6.3) for HT and 3.3 ± 1.4 min (range 1.9-5.2) for SaS-
IMRT, with a significant difference between these values
(p = 0. 00). The mean MU/fr used was 5135 ± 1678 for
HT, which was significantly higher than the mean MU/fr
of 343 ± 120 in SaS-IMRT (p < 0.05).
For group 2, the mean delivery time was 4.7 ± 0.8 min
(range 3.3-5.7) for HT and 6.2 ± 1.4 min (range 4.8-8.8)
for SaS-IMRT. A significant difference was observed
between these values (p < 0.05). The mean MU/fr used
was 5529 ± 960 for HT, which was significantly higher
than the mean MUs of 461 ± 242 in SaS-IMRT (p < 0.05).
Discussion
The benefits of improved dose homogeneity and better
sparing of critical organs in HT compared with conven-
tional linac-based IMRT have been reported in prostate
Figure 1 The comparison of isodose distributions of planned target volume (PTV) and organs at risk (OARs) in an axial plane for one patient 
in group 1 using the helical tomotherapy (HT) planning system versus step-and-shoot intensity-modulated radiotherapy (SaS-IMRT). DVH: 
Dose volume histograms; PTV = Planning target volume; OAR = Organ at risk
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cancer [46], intracranial tumours [24], nasopharyngeal
carcinoma [22] and other head and neck cancers [47,48],
and breast cancer [13]. However, these benefits of IMRT
and HT are generally achieved at the cost of a greater vol-
ume of normal tissue in the irradiated volume receiving a
low dose [29,49]. In addition, radiotherapy for liver
tumours is largely limited by the dose to the surrounding
normal tissues, primarily the residual normal liver tissue.
One of the major objectives of this study was to deter-
mine the achievable gain of HT in single and multiple
liver tumour irradiations against a well-investigated and
routinely-used clinical technique, SaS IMRT, delivered in
a conventional way with SaS-IMRT planning and an
Elekta Precise delivery system. Sixteen cases in two
groups were investigated in this study. The HT plans had
a slightly significantly better conformity and homogene-
ity to the PTV than SaS-IMRT plans in the whole cohort.
However, the dosimetric advantages of the two plans
were inconsistent for individual OARs and other indices.
We demonstrated that HT plans significantly improved
the conformity index (improvement ratio: 7 and 14%) and
homogeneity index (improvement ratio: 2 and 4%) of the
PTV compared with SaS-IMRT plans in group 1 and 2,
respectively.
However, the difference between the mean/maximal
doses of OARs was not statistically significant in group 1,
indicating no difference in OARs sparing. Sparing was
found in the normal liver with mean values of QI-1 = 0.95
± 0.20 and QI-2 = 0.90 ± 0.14, and in the spinal cord with
Figure 2 The comparison of isodose distributions of planned target volume (PTV) and organs at risk (OARs) in an axial plane for one patient 
in group 2 using the helical tomotherapy (HT) planning system versus step-and-shoot intensity-modulated radiotherapy (SaS-IMRT). DVH: 
Dose volume histograms; PTV = Planning target volume; OAR = Organ at risk
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mean values of QI-1 = 0.86 ± 0.47 and QI-2 = 0.83 ± 0.30
in group 2, indicating a dosimetric gain in the HT plans.
In  V30 Gy and  V50% analysis, HT showed a significant
dosimetric gain in group 2. The results showed that a bet-
ter (lower) dose was received in HT than that in group 1;
for group 2, the mean value of V50% of the whole liver was
36.46 ± 4.92 for HT and 51.74 ± 11.46 for SaS-IMRT,
indicating an approximate reduction of 15.3% in HT. The
mean value of V30 Gy of the normal liver was 43.91 ± 10.43
for HT and 55.00 ± 14.28 for SaS-IMRT, indicating an
approximate reduction of 11.1% in HT. These results
showed a significant dosimetric gain in HT and a reduced
mean liver dose.
In clinical practice, the V50% (fraction of normal liver
treated to at least 50% of the isocentre dose) and the V30
Gy (the percentage volume receiving a dose greater than
or equal to 30 Gy for the whole liver) are the most com-
monly used indicators for the dose given. According to
the Yonsei University guidelines [50], if the percentage of
normal liver volume receiving 50% of the isocentre dose
was less than 25%, the total dose was increased to 59.4
Gy; if the percentage was 25% to 49%, the dose was 45 to
54 Gy; if the percentage was 50% to 75%, the dose was
30.6 to 45 Gy, and if the dose was more than 75%, no
treatment was administered. They showed that the
parameter V50% can be divided into four categories and
used to predict acceptable liver toxicity. In group 2, the
V50% value of normal liver was 36.46 ± 4.92% for HT and
51.74 ± 11.46% for SaS-IMRT, indicating an opportunity
for dose escalation by HT versus SaS-IMRT plans. The
NTCP value of the normal liver was 2.38 ± 2.25% for HT
and 20.27 ± 13.29% for SaS-IMRT, indicating that a
reduction in tissue complications may be achieved by HT
versus SaS-IMRT plans.
Kim et al. demonstrated that the V30 Gy appears to be a
useful dose-volumetric parameter for predicting the risk
of radiation-induced hepatic toxicity (RIHT). In their
report, grade 2 or worse RIHT was observed in only 2 out
of 85 patients (2.4%) with a whole liver volume receiving
30 Gy (V30 Gy, whole liver) of ≤60%, and in 11 out of 20
patients (55.0%) with greater than 60% (p < 0.001) [12].
When a lower value of V50% and/or V30 Gy was accom-
plished, a higher PTV dose could be given. As a result, a
lower V50% and/or V30 Gy can be achieved with HT for the
treatment of multiple liver tumours than with SaS-IMRT.
Consequently, a higher dose can be given and a higher
response can be achieved when HT is selected.
The overall delivery time and average MU/fr used in
the HT plans were significantly higher than for SaS-
IMRT plans, which are consistent with the results of sev-
eral studies [13,22,24,47-49]. The delivery time depended
on the limitations of gantry rotation and dose prescrip-
tion in the HT system, while a speed limitation on gantry
rotation exists in the HT system. An interesting result
occurred in this study in that a contrary result was found
in group 2 due to the geometry of the multiple site distri-
bution. The mean delivery time in group 2 was 4.7 ± 0.8
min (range 3.3-5.7) for HT and 6.2 ± 1.4 min (range 4.8-
8.8) for SaS-IMRT. This difference was significant (p = 0.
01).
We also found that both planning systems satisfied the
required PTV prescription, but that better dose confor-
mity and homogeneity were achieved with the HT com-
Table 2: The dosimetric results of PTV between HT and SaS-IMRT plans for two groups
Parameter objective HT SaS-IMRT p
Group 1-single tumour group
V95% 100 99.44 ± 0.72(97.97-100.00) 99.63 ± 0.51(98.78-100.00) n/a
V100% 95 97.26 ± 1.13(95.87-98.79) 97.84 ± 0.99(96.50-99.07) n/a
V107% 0 0.00 ± 0.00 8.75 ± 4.94(2.30-15.14) < 0.05
CI 1 1.21 ± 0.07(1.15-1.37) 1.30 ± 0.05(1.23-1.40) < 0.05
HI 1 1.04 ± 0.01(1.02-1.05) 1.06 ± 0.01(1.02-1.07) < 0.05
Group 2-multiple tumours group
V95% 100 99.09 ± 0.45(98.43-99.95) 98.47 ± 0.69(97.35-99.25) n/a
V100% 95 96.20 ± 0.70(95.60-97.86) 96.13 ± 1.10(94.80-97.77) n/a
V107% 0 0.30 ± 0.58(0.00-1.60) 16.62 ± 2.38(13.70-20.53) < 0.05
CI 1 1.25 ± 0.11(1.15-1.47) 1.43 ± 0.07(1.37-1.57) < 0.05
HI 1 1.06 ± 0.01(1.02-1.07) 1.10 ± 0.02(1.08-1.12) < 0.05
Abbreviation: SaS-IMRT: Step-and-shoot intensity-modulated radiotherapy; HT: Helical tomotherapy; Vx%: volume receiving ≥x% of the 
prescribed dose; CI: Conformity index; HI: Homogeneity index; n/a: not statistical significance; statistical significance (p < 0.05) is reported 
between couples from the paired Wilcoxon signed-rank test analysis.Lee et al. Radiation Oncology 2010, 5:58
http://www.ro-journal.com/content/5/1/58
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pared to SaS-IMRT plans in the two groups. No
significant was shown for OARs sparing in group 1, espe-
cially if the tumour is leaning against the body surface. As
the result, general SaS-IMRT can meet the prescription
requirements like the HT did, but shown more efficiency
in MU/fr used and delivery time saved than HT in group
1.
We did not aim to perform a strict comparison of the
two systems, but to retrospectively evaluate the dosimet-
ric difference for the 16 patients that had been success-
fully treated with step-and-shoot IMRT and re-planned
in a routinely-used helical tomotherapy based upon the
same planning CT scan; the dose plans were made by the
same physicist and approved by the same oncologist who
was specialized in liver tumours. We paid careful atten-
tion to reducing biases in this study. However, there are
some limitations with regard to our results, and although
we used the same resolution, voxel size, and binning of
Table 3: Dosimetric statistics for the specified OARs
Structure Parameter HT SaS-IMRT p
Group 1-single tumour group
Normal liver Mean (Gy) 18.24 ± 6.73(10.84-31.09) 20.01 ± 7.86 (8.37-31.20) n/a
V50%(%) 19.17 ± 5.62(10.83-22.50) 22.19 ± 7.13(14.17-31.25) n/a
EUD 23.68 ± 5.14(16.60-33.97) 29.11 ± 5.46(21.52-37.14) < 0.05
NTCP 1.69 ± 4.30(0.003-12.33) 6.80 ± 9.86(0.06-29.07) 0.051
Whole liver V30 Gy(%) 36.41 ± 14.88(16.45-62.00) 39.44 ± 16.57(16.94-62.06) n/a
Lt kidney Mean (Gy) 2.48 ± 2.43 (0.30-6.44) 2.83 ± 3.61(0.17-9.00) n/a
Rt kidney Mean (Gy) 4.13 ± 3.09 (0.42-8.03) 5.55 ± 4.55(0.15-10.57) n/a
GIS Max (Gy) 30.18 ± 18.17(8.65-52.56) 32.67 ± 17.27(11.77-53.45) n/a
Spinal cord Max (Gy) 15.30 ± 9.14(5.12-34.28) 22.05 ± 11.10(4.58-34.78) n/a
Group 2-multiple tumours group
Normal liver Mean (Gy) 25.89 ± 3.43(18.89-28.45) 29.73 ± 6.71 (15.54-36.96) < 0.05
V50%(%) 36.46 ± 4.92(29.17-41.67) 51.74 ± 11.46(37.5-69.17) < 0.05
EUD 28.09 ± 3.23(21.95-31.87) 34.68 ± 3.80(27.77-38.43) < 0.05
NTCP 2.38 ± 2.25(0.07-6.15) 20.27 ± 13.29(1.23-38.33) < 0.05
Whole liver V30 Gy(%) 43.91 ± 10.43(23.12-53.42) 55.00 ± 14.28(27.11-74.97) < 0.05
Lt kidney Mean (Gy) 4.18 ± 2.94 (0.66-9.21) 2.60 ± 2.03(0.37-6.97) n/a
Rt kidney Mean (Gy) 6.11 ± 4.16 (0.99-12.38) 6.45 ± 4.76(0.93-14.58) n/a
GIS Max (Gy) 39.59 ± 12.42(21.42-53.20) 42.05 ± 12.36(19.67-52.78) n/a
Spinal cord Max (Gy) 18.08 ± 5.38(10.58-28.19) 23.66 ± 8.65(8.96-32.20) < 0.05
Abbreviation: SaS-IMRT: Step-and-shoot intensity-modulated radiotherapy;; HT: helical tomotherapy; EUD: Equivalent uniform dose; NTCP: 
Normal tissue complication probability; GIS: Gastrointestinal system (including stomach and small bowels); Lt: left side; Rt: right side; n/a: not 
statistical significance; statistical significance (p < 0.05) is reported between couples from the paired Wilcoxon signed-rank test analysis.
Table 4: The dosimetric comparisons of QI between HT and SaS-IMRT plans
Variables of OARs QI-1 QI-2 QI-whole cohort
QI of parallel organ
Normal Liver 0.95 ± 0.20 (0.61-1.30) 0.90 ± 0.14 (0.76-1.21) 0.93 ± 0.17 (0.61-1.30)
QI of serial organ
SC 0.86 ± 0.47 (0.16-1.45) 0.83 ± 0.30 (0.56-1.52) 0.85 ± 0.38 (0.16-1.52)
GIS 0.91 ± 0.23 (0.64-1.36) 0.95 ± 0.12 (0.75-1.11) 0.93 ± 0.18 (0.64-1.36)
Abbreviation: HT: Helical tomotherapy; SaS-IMRT: Step-and-shoot intensity-modulated radiotherapy; QI: Quality index; QI-1: QI-single tumour 
group; QI-2: QI-multiple tumours group; SC: Spinal cord; GIS: Gastrointestinal system (including stomach and small bowels);Lee et al. Radiation Oncology 2010, 5:58
http://www.ro-journal.com/content/5/1/58
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the DVHs in both systems, and the same software
(CERR), an intrinsic difference in the calculation algo-
rithms or TPS optimization modules (such as DMPO)
might produce different results.
Conclusions
Our study suggests the dosimetric benefits of HT over
SaS-IMRT plans in the group with multiple liver
tumours, especially with regards sparing of OARs, as it
significantly reduced the V50% and V30 Gy to the normal
liver and whole liver respectively. In addition a reduction
in the NTCP value indicates that fewer tissue complica-
tions may arise in HT plans. Although there was no sig-
nificant difference in the group with single liver tumour,
IMRT showed better efficiency in terms of the MU/fr and
delivery time used.
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